Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
An Eli Lilly insulin manufacturing facility in France. Photo: Frederick Florina/AFP/Getty Images
Eli Lilly’s decision to start selling a new version of its most popular fast-acting insulin highlights the industry’s concerns about possible legislation or regulation to rein in drug prices.
Reality check: Some diabetic patients will benefit from Lilly's new authorized generic, called Lispro. But the PR-heavy move, which has been replicated for other controversially priced medicines, isn't structural change. It aligns with the Trump administration's goal of lowering prices at the pharmacy counter — not necessarily what the system overall pays.
By the numbers: Humalog, which generated $3 billion of revenue for Lilly in 2018, has a list price of $275 per vial. Lispro’s list price will be half that.
Yes, but: A Lilly spokesperson confirmed that Lispro's price will be "comparable" to what Humalog costs after accounting for rebates and discounts.
- There's no guarantee health insurers or pharmacy benefit managers will cover Lispro, and it's highly unlikely Lilly will offer sizable rebates, if any, for this insulin product.
- A spokesperson said the company is "not able to comment or speculate on what the rebates will be."
We’ve seen this movie before.
- Mylan created an authorized generic for its EpiPens in 2016.
- Gilead created authorized generics for its hepatitis C medications last year.
- Releasing authorized generics allows companies to compete with themselves, which benefits them more than cutting the price of the brand-name drug.
The bottom line: Lilly's generic insulin will help people with diabetes who don't have insurance, or who face high deductibles and coinsurance rates.
- But it will not fundamentally change what the country pays for this kind of insulin — or others versions of insulin.
- Patient advocates who have diabetes pointed out that at $140 per vial, Lispro will still cost 7 times as much as the same insulin in other developed countries.
Go deeper: Axios' special report on drug pricing